

# Use of Polymerase Chain Reaction and Endonuclease Restriction *BccI* for the differential *Leptospira interrogans* detection

Javier Bravo Músare, Carlos Navarro Venegas.

Microbiology Laboratory. Department of Preventive Animal Medicine. FAVET. University of Chile, Chile

\*Corresponding Author: (56-2) 29785627. canavarr@uchile.cl

**Abstract:** *Leptospirosis* is a world disease, affecting animals and humans, which is transmitted by all infected animal, having the rodents as the most recognized. *Leptospira interrogans* serovar *canicola*, *Leptospira interrogans* serovar *icterohaemorrhagiae*, *Leptospira interrogans* serovar *pomona* and *Leptospira interrogans* serovar *grippotyphosa* affect canines, pigs, horses and cattle. A differential diagnosis method of four *Leptospira* serovars is our objective, through the molecular technique of the Polymerase Chain Reaction (PCR) adding the action of the restriction enzyme *BccI*, and thus generate fragments of different size for the recognition of the gene encoding a lipoprotein membrane *LipL32*. As conclusion, the detection of *Leptospira interrogans* by PCR was possible by that the primers designed for the realization of the method are specific for this agent. The differentiation of the 4 serovars of *Leptospira* was successful because the restriction enzyme cleaves the double strand of DNA in the 4 serovars, delivering expected results.

**Keywords:** *Leptospira*, PCR, restriction endonuclease, *BccI*, *LipL32*.

## 1. Introduction

Leptospirosis is probably the most disseminated zoonosis in the world (Adler 2014). The microorganism infects a large variety of mammals, both domestic and wild, and the picture usually presents an abrupt onset with fever, myalgia and headache. Although most cases are mild or moderate, the clinical course is complicated by renal failure, uveitis, pulmonary hemorrhage, respiratory distress, myocarditis, rhabdomyolysis and meningitis (Olmo *et al.*, 2014). Normally dogs are vaccinated against two of the serovars of *Leptospira interrogans*: *canicola* and *icterohaemorrhagiae*, but this does not ensure complete immunity. Thus, to make an early and appropriate therapeutic decision, veterinarians have differentiated leptospirosis from other diseases, such as piroplasmosis or parvoviral enteritis, whose clinical signs are like those of leptospirosis, but which require completely different treatments. At present, the presence of infection is determined by the microscopic agglutination test (MAT), however, its results are ambiguous since agglutination occurs both because of the same vaccination and as an infection (Andre-Fontaine *et al.*, 2015). *Leptospira* are Gram-negative, helical bacteria, belong to the genus *Leptospira*, family *Leptospiraceae*, *spirochetal* order (Adler and de la Peña Moctezuma, 2010). DNA studies, determined its taxonomic classification. This is how the genus *Leptospira* includes three non-pathogenic species: *L. biflexa*, *L. meyerii*, *L. wolbachii*, and seven pathogenic species: *L. borgpetersenii*, *L. inadai*, *L. interrogans*, *L. kirschneri*, *L. noguchii*, *L. santarosai* and *L. weilii*; that contemplate 24 serogroups and 237 serovars (Zunino and Pizarro, 2007). A hook-shaped end is characteristic in *Leptospira*. It has two flagella, which are responsible for the movement of the spirochete (Adler and de la Peña Moctezuma, 2010). The genome of *L. interrogans*, consists of 4,691,184 base pairs (bp). It consists of two circular chromosomes, a large one of 4,332,241 bp and a smaller one of approximately 358,943 bp (Xiren *et al.*, 2003).

The Polymerase Chain Reaction (PCR) is an efficient molecular technique to achieve the diagnosis of leptospirosis in a fast, sensitive and specific way. This method has been used above all for the diagnosis of microorganisms difficult to grow and this is how several researchers have used it to detect serovars of *Leptospira* in the different clinical cases in which infection with this agent is suspected. In this context, in the present report it is proposed to use the PCR technique using as detection target the *LipL32* protein gene, a lipoprotein expressed in the outer membrane of the bacterium and highly conserved among the pathogenic species of *Leptospira* spp. (Cullen *et al.*, 2002) in association with enzymatic digestion by means endonucleases a molecular method that allows to discriminate between *Leptospira interrogans* serovar *canicola*, *L. interrogans* serovar *pomona*, *L. interrogans* serovar *icterohaemorrhagiae* and *L. interrogans* serovar *grippotyphosa*, contributing to the epidemiological study of the disease (Jung *et al.*, 2015).

The main difference between with previous studies is the differentiation between the 4 serovars of *L. interrogans*, through the action of a restriction endonuclease *BccI*. The selection of this enzyme was carried out thanks to the free access program Neb cutter™. It was sought that this 480 bp amplicon was digested by the restriction enzyme *BccI* to differentiate between *L. interrogans* serovar *canicola* (LIC; AJ580493.1), *L. interrogans* serovar *Pomona* (LIP; EU871716.1), *L. interrogans* serovar *Icterohaemorrhagiae* (LII; AB094433.2) and *L. interrogans* serovar *grippotyphosa* (LIG; JN886738.1).

It should be noted that the restriction enzyme cleaved double-stranded DNA concomitantly with the detection of a specific base sequence. Thus, the *BccI* enzyme -isolated from *Bacteroides caccae*- recognizes the nucleotide sequence: CCATCNNNNNN (Genbank, 2015).

## 2. Materials and Methods

The work was carried out in the Virology and Microbiology Laboratories of the Department of Preventive Animal Medicine, University of Chile and in the Laboratory of Leptospira of the Agricultural and Livestock Service of Chile (SAG).

**Implement the conventional PCR protocol:** Pure strains obtained from cultures of the Leptospirosis unit of the bacteriology laboratory of SAG were used: the following serovars: *Leptospira interrogans* serovar canicola (LIC), *Leptospira interrogans* serovar icterohaemorrhagiae (LII), *Leptospira interrogans* serovar pomona (LIP) and *Leptospira interrogans* serovar grippityphosa (LIG). As a negative control, *Salmonella* Typhimorium DNA was used. Nucleate-free water (NFW) was used as reagent control.

### 2.1 Obtaining DNA from Leptospira

DNA extraction was carried out using a commercial kit (High pure PCR template preparation kit Roche)

### 2.2. Primers

In the PCR technique, the primers JB1 were used: 5'-ATGTTTGGATTCTGCGTA-3' and JB2: 5'-GGCTC ACACCTGGAATACCT-3' generated by the Oligoperfect Design program (Invitrogen, Ltd.) for free online access to obtain an amplicon of 480 base pairs. The design of the primers was based on the alignment of the four serovars and the choice of the genomic zone that involves the nucleotide differences found according to the Clustal Omega free online program (Annexes 1 and 2). The reconstitution of each of the primers with nuclease-free water, led to the final obtaining of both primers at a concentration of 1 µM.

### 2.3 Reaction mixture

15 µL of the Master Mix Go taq® Green 2x PROMEGA M712b solution, 5 µL of the template DNA and 5 µL of each specific primer was used, reaching a final volume of 30 µL.

### 2.4 DNA amplification

The samples were taken to the Apollo® thermocycler and subjected to a DNA denaturation step at 94° C for 30 seconds, a stage of alignment of the starters at 55° C for 30 seconds and an elongation stage at 72° C for 30 seconds, to complete a cycle, requiring 30 cycles to perform the method. After 30 cycles, the amplified product was visualized.

### 2.5 Visualization of the amplified product

It was carried out by electrophoresis in 2% agarose gel (Winkler®) and was carried out at 90 V for 90 minutes. As a molecular size marker, AccuRuler 100 bp Ladder Maestrogen® was used, ranging from 100 to 3000 base pairs. The gel was incubated in ethidium bromide (0.5 µg/mL) (Fermelo®) for 40 minutes and then placed in a ultraviolet light Transiluminator UVP®. Finally, the gel was photographed to obtain a record of the results.

### 2.6 Obtaining a typical digestion pattern for each serovar of Leptospira interrogans

Each DNA fragment obtained in PCR was digested with the

restriction enzyme *BccI*. To start the digestion, the 4 tubes were placed in an oven at 37° C for 1 hour and 20 minutes, and to inactivate the enzyme, these tubes were taken to a 65° C bath for 20 minutes. The visualization of the digested and undigested fragments was carried out in the same way as mentioned above.

### 2.7 Biosafety regulations.

Use of clean and closed aprons, use of clean material and proper disposal of waste. Regarding the PCR procedure and subsequent electrophoresis, latex gloves should be used both to avoid contamination of the sample and to manipulate substances such as ethidium bromide, which has mutagenic properties. When using the transilluminator, glasses with UV filter and an acrylic plate located between the equipment and the person who visualized the gel were used.

## 3. Results

### 3.1 Detection by PCR of the *lipL32* gene in strains of *L. interrogans*.

The visualization of amplicons by the PCR technique with the designed *in silico* primers show in all the samples a single band around 500 bp. No bands were observed in the lanes assigned to the negative control or the reagent control. (Figure 1).

### 3.2 Determination of the utility of the *BccI* enzyme in *L. interrogans* to differentiate between serovars *pomona*, *icterohaemorrhagiae*, *canicola* and *grippityphosa* of *L. interrogans*.

After the digestion of the DNA fragments products of the PCR technique used, several fragments of different sizes are observed in each lane, according to Figure 2.

## 4. Discussion

The PCR protocol implemented with the primers designed *in silico*, was able to detect unique fragments of the expected size (≈500 bp), which is certainly a contribution to the general detection of *Leptospira*. In addition, when carrying out the enzymatic digestion with *BccI*, the expected pattern was obtained, since single bands of around 480 to 70 bp were observed in each of the digested fragments and PCR products (Anexx 4).

These results were expected considering the cut-off sites of the acquired restriction enzyme. Theoretically, the restriction enzyme would generate a differential profile according to each serovar. Thus, by observing the electrophoretic pattern, the utility of endonuclease use can be clearly established.

The use of restriction enzymes in differential detection between serovars of *Leptospira* has been reported recently, but using 2 or more restriction enzymes such as *BasII*, *FokI*, *HaeIII*, *Hyp8I* and *TaqII* for the digestion of amplicons generated by PCR (Wajjwalku *et al.*, 2015).

This represents an important difference with our work in terms of using two or more enzymes for the differentiation of serovars.

Currently, other genes have been described as targets for detection of *Leptospira*: the *flab* gene (Wajjwalku *et al.*,

2015) or the  $\beta$ -subunit gene of RNA polymerase (Jung *et al.*, 2015), which increases the number of targets for detection by PCR and subsequent digestion with one, or with several restriction enzymes. However, it has been described that the *lip132* gene is the most conserved in the pathogenic species of *Leptospira*, which makes it suppose that it has an infective character, even though its role is not absolutely clear (Murray 2013).


In summary, the *BccI* constitutes a great choice for the differentiation of *Leptospira* serovars.

## 5. Conclusion


Without a doubt, the molecular detection of *Leptospira interrogans* is a reality, since it is demonstrated with the use of the PCR protocol already described. There is no debt in the differential detection of serovars, which according to the literature and the use of the *online* program NEB cutter allowed to obtain a very encouraging result with the use of *BccI*.

## References

- [1] Adler, B.(2014). Pathogenesis of leptospirosis: Cellular and molecular aspects. *Vet Microbiol*, 172, 353-358.
- [2] AdlerB, De La Peña Moctezuma A. 2010. *Leptospira* and leptospirosis. *Vet Microbiol*140:287-296.
- [3] Andre-FontaineG, Aviat F, Marie J, Chatrenet B.2015. Undiagnosed leptospirosis cases in naive and vaccinated dogs: Properties of a serological test based on a synthetic peptide derived from Hap1/LipL32. *Comp Immunol Microb*. 39:1-8.
- [4] Clustal Omega. (2016). Multiple sequence alignment. [Online] Available: <http://www.ebi.ac.uk/Tools/msa/clustalo/> (December 12, 2017)
- [5] Cullen, P., Cordwell, S., Bulach,D., Haake,D., Adler,B. (2002). Global Analysis of Outer Membrane Proteins from *Leptospira interrogans* serovar *Lai*. *Infect Immun*70, 2311–2270
- [6] Oligo perfect™ Designer. (2005). [Online] Available: <https://tools.thermofisher.com/content/cfm?pageid=9716&icid=fr-oligo-6?CID=fl-oligoperfect> (November 12, 2017)
- [7] Genbank. (2015). [Online] Available: <http://www.ncbi.nlm.nih.gov/genbank/> (January 16, 2018)
- [8] Jung,L., Quaresma,M., Geessien, E., & Cantini,A. (2015). Identification of *Leptospira* serovars by RFLP of the RNA polymerase beta subunitgene (*rpoB*). *BrazJ Microbiol*, 46, 465-476.
- [9] NEBcutter. (2013). New England Bio Labs. Inc.[Online] Available: <http://www.neb.com> (December 12, 2017)
- [10] Olmo, F., Peñas, C., Sojo, J., Muniáin,M. 2014. Leptospirosis. *Medicine* 11, 3003-3008
- [11] Wajjwalkul, W., Sukmak, M., Amavisit, P., Sukpuaram, T., & La-ArdA. (2015). Molecular characterization of *FlaB*for *Leptospira* Identification. *Southeast Asian J Trop Med Public Health*, 46, 262-467.
- [12] WHO.(2003).Human leptospirosis: guidance for diagnosis, surveillance and control.[Online] Available: [http://www.who.int/csr/don/en/WHO\\_CDS\\_CSR\\_EPH\\_2002.23.pdf](http://www.who.int/csr/don/en/WHO_CDS_CSR_EPH_2002.23.pdf) (August13, 2017)
- [13] Xiren, S., Fu, G. & Jiangk, X. (2003). Unique physiological and pathogenic features of *Leptospira interrogans* revealed by whole-genomes sequencing. *Nature* 422, 888-892
- [14] Zunino E, Pizarro R. 2007. Leptospirosis: Puesta al día. *Rev Chil Infectol* 24, 220-226.



**Figure 1**  
 Agarose gel electrophoresis of the *lipL32* gene for *Leptospira interrogans*.  
 Lane 1: LIC. Lane 2: LII. Lane 3: LIP. Lane 4: Lane 5: negative control.  
 Lane 6: control of reagents. Lanes 7, 8,9: Empty. Lane 10: molecular size marker



**Figure 2**  
 Agarose gel electrophoresis. Digestion with *BccI* for *Leptospira interrogans*.  
 Lane 1: LIC (PCR). Lane 2: LIP (PCR). Lane 3: LII (PCR). Lane 4: LIG (PCR).  
 Lane 5: LIC (restriction). Lane 6: LIP (restriction). Lane 7: LII (restriction).  
 Lane 8: LIG (restriction). Lane 9 empty. Lane 10: molecular size marker

**Anexx 1:** Nucleotide sequences from *Leptospira interrogans* serovars.

>AJ580493: *Leptospira interrogans* serovar *canicola*: LIC

ATGAAAAAAGCTTTTCGATTTTGGCTATCTCCGTTGCAAGCATTACCGCTTGTGGTGCTTTTCGGTGGTCTG  
CCAAGCCTAAAAAGCTCTTTTGTCTGAGCGAGGACACAATCCCAGGGACAAACGAAACCGTAAAAACGTTACTCCCT  
ACGGATCTGTGATCAACTATTACGGATACGTAAAGCCAGGACAAAGCGCCGGACGGTTTAGTCGATGGAAACAAAAAG  
CATACTATCTCTATGTTTGGATTCTGCGTAATCGCTGAAATGGGAGTTTCGTATGATTTCCCCAACAGGCGAAATCG  
GTGAACCAGGCGACGGAGACTTAGTAAGCGACGCTTTCAAAGCGGCTACCCAGAAGAAAAATCAATGCCACATTGGT  
TTGATACTTTGGATCCGTGTAGAAAGAATGTCGGCGATTATGCCTGACCAAATCGCCAAAGCTGCGAAAGCAAAACAG  
TTCAAAAATTGGACGATGATGATAATGGTGACGATACTTATAAAGAAGAGAGACACAACAAGTACAACCTCTCTACTA  
GAATCAAGATCCCTAATCCTCCAAAATCTTTGACGATCTGAAAAACATCGACACTAAAAAACTTTTAGTAAGAGGTC  
TTTACAGAATTTCTTTTACTACCTACAAACCAGGTGAAGTGAAAGGATCTTTCGTTGCATCTGTTGGTCTGCTTTTTC  
CACCAGGTATTCCAGGTGTGAGCCCGCTGATCCACTCAAATCCTGAAGAATTGCAAAAACAAGCTATCGCTGCTGAAG  
AGTCTTTGAAAAAGCTGCTTCTGACGCGACTAAGTAA

>AB094433.2: *Leptospira interrogans* serovar *icterohaemorrhagiae*: LII

TTACCGCTTGTGGTGCTTTTCGGTGGTCTGCCAAGCCTAAAAAGCTCTTTTGTCTGAGCGAGGACACAATCCCAGGGA  
CAAACGAAACCGTAAAAACGTTACTTCCCTACGGATCTGTGATCAACTATTACGGATACGTAAAGCCAGGACAAGCGC  
CGGACGGTTTAGTCGATGGAAACAAAAAGCATACTATCTCTATGTTTGGATTCTGCGTAATCGCTGAAATGGGAG  
TTCGTATGATTTCCCCAACAGGCGAAATCGGTGAGCCAGGCGACGGAGACTTAGTAAGCGACGCTTTCAAAGCGGCTA  
CCCCAGAAGAAAAATCAATGCCACATTGGTTTGATACTTTGGATCCGTGTAGAAAGAATGTCGGCGATTATGCCTGACC  
AAATCGCCAAAGCTGCGAAAGCAAAACCAGTTCAAAAATTGGACGATGATGATGATGGTGACGATACTTATAAAGAAG  
AGAGACACAACAAGTACAACCTCTCTACTAGAAATCAAGATCCCTAATCCTCCAAAATCTTTTGACGATCTGAAAAACA  
TCGACACTAAAAAACTTTTAGTAAGAGGTCTTTACAGAATTTCTTTTCACTACCTACAAACCAGGTGAAGTGAAAGGAT  
CTTTTCGTTGCATCTGTTGGTCTGCTTTTCCCACCAGGTATTCCAGGTGTGAGCCCGCTGATCCACTCAAATCCTGAAG  
AATTGCAAAAACAAGCTATCGCTGCT

>JN886738.1: *Leptospira interrogans* serovar *grippityphosa*: LIG

ATGAAAAAAGCTTTTCGATTTTGGCTATCTCCGTTGCAAGCATTACCGCTTGTGGTGCTTTTCGGTGGTCTG  
CCAAGCCTAAAAAGCTCTTTTGTCTGAGCGAGGACACAATCCCAGGGACAAACGAAACCGTAAAAACGTTACTTCCC  
TACGGATCTGTGATCAACTATTACGGATACGTAAAGCCAGGACAAGCGCCGGACGGTTTAGTCGATGGAAACAAAAAA  
GCATACTATCTCTATGTTTGGATTCTGCGTAATCGCTGAAATGGGAGTTTCGTATGATTTCCCCAACAGGCGAAATC  
GGTGAACCAGGCGATGGAGACTTAGTAAGCGACGCTTTCAAAGCGGCTACCCAGAAGAAAAATCAATGCCACATTGG  
TTTGATACTTTGGATCCGTGTAGAAAGAATGTCGGCGATTATGCCTGACCAAATCGCCAAAGCTGCGAAAGCAAAACCC  
GTTCAAAAATTGGACGATGATGATGATGGTGACGATACTTATAAAGAAGAGAGACACAATAAGTACAACCTCTCTTACT  
AGAATCAAGATCCCTAATCCTCCAAAATCTTTTGACGACCTGAAAAACATCGATACTAAAAAACTTTTAGTAAGAGGT  
CTTTACAGAATTTCTTTTCACTACCTACAAACCAGGTGAAGTGAAAGGATCTTTCGTTGCATCTGTTGGTCTGCTTTTC  
CCACCAGGTATTCCAGGTGTGAGCCCGCTGATCCACTCAAATCCTGAAGAATTGCAAAAACAAGCTATCGCTGCTGAA  
GAGTCTTTGAAAAAGCTGCTTCTGACGCGACTAAGTAA

>EU871716.1: *Leptospira interrogans* serovar *pomona*: LIP

ATGAAAAAAGCTTTTCGATTTTGGCTATCTCCGTTGCAAGCATTACCGCTTGTGGTGCTTTTCGGTGGTCTG  
CCAAGCCTAAAAAGCTCTTTTGTCTGAGCGAGGACACAATCCCAGGGACAAACGAAACCGTAAAAACGTTACTTCCC  
TACGGATCTGTGATCAACTATTACGGATACGTAAAGCCAGGACAAGCGCCGGACGGTTTAGTCGATGGAAACAAAAAA  
GCATACTATCTCTATGTTTGGATTCTGCGTAATCGCTGAAATGGGAGTTTCGTATGATTTCCCCAACAGGCGAAATC  
GGTGAACCAGGCGACGGAGACTTAGTAAGCGACGCTTTCAAAGCGGCTACCCAGAAGAAAAATCAATGCCACATTGG  
TTTGATACTTTGGATCCGTGTAGAAAGAATGTCGGCGATTATGCCTGACCAAATCGTCAAAGCTGCGAAAGCAAAACCA  
GTTCAAAAATTGGACGATGATGATGATGGTGACGATACTTATAAAGAAGAGAGACACAACAAGTACAACCTCTCTTACT  
AGAATCAAGATCCCTAATCCTCCAAAATCTTTTGACGATCTGAAAAACATCGACACTAAAAAACTTTTAGTAAGAGGT  
CTTTACAGAATTTCTTTTCACTACCTACAAACCAGGTGAAGTGAAAGGATCTTTCGTTGCATCTGTTGGTCTGCTTTTC  
CCACCAGGTATTCCAGGTGTGAGCCCGCTGATCCACTCAAATCCTGAAGAATTGCAAAAACAAGCTATCGCTGCTGAA  
GAGTCTTTGAAAAAGCTGCTTCTGACGCGACTAAGTAA



**Anexx 2: Alignment of nucleotide sequences according Clustal  $\Omega$**

LIC	GGTGCTTTTCGGTGGTCTGCCAAGCCTAAAAAGCTCTTTTGTCTGAGCGAGGACACAATC	120
LIG	GGTGCTTTTCGGTGGTCTGCCAAGCCTAAAAAGCTCTTTTGTCTGAGCGAGGACACAATC	120
LII	GGTGCTTTTCGGTGGTCTGCCAAGCCTAAAAAGCTCTTTTGTCTGAGCGAGGACACAATC	71
LIP	GGTGCTTTTCGGTGGTCTGCCAAGCCTAAAAAGCTCTTTTGTCTGAGCGAGGACACAATC	120
*****		
LIC	CCAGGGACAAACGAAACCGTAAAAACGTTAC-TCCCTACGGATCTGTGATCAACTATTAC	179
LIG	CCAGGGACAAACGAAACCGTAAAAACGTTACTTCCCTACGGATCTGTGATCAACTATTAC	180
LII	CCAGGGACAAACGAAACCGTAAAAACGTTACTTCCCTACGGATCTGTGATCAACTATTAC	131
LIP	CCAGGGACAAACGAAACCGTAAAAACGTTACTTCCCTACGGATCTGTGATCAACTATTAC	180
*****		
LIC	GGATACGTAAAGCCAGGACAAGCGCCGGACGGTTTAGTCGATGGAACAAAAAAGCATAC	239
LIG	GGATACGTAAAGCCAGGACAAGCGCCGGACGGTTTAGTCGATGGAACAAAAAAGCATAC	240
LII	GGATACGTAAAGCCAGGACAAGCGCCGGACGGTTTAGTCGATGGAACAAAAAAGCATAC	191
LIP	GGATACGTAAAGCCAGGACAAGCGCCGGACGGTTTAGTCGATGGAACAAAAAAGCATAC	240
*****		
LIC	TATCTCTATGTTTGGATTCTGCGGTAATCGCTGAAATGGGAGTTCGTATGATTTCCCCA	299
LIG	TATCTCTATGTTTGGATTCTGCGGTAATCGCTGAAATGGGAGTTCGTATGATTTCCCCA	300
LII	TATCTCTATGTTTGGATTCTGCGGTAATCGCTGAAATGGGAGTTCGTATGATTTCCCCA	251
LIP	TATCTCTATGTTTGGATTCTGCGGTAATCGCTGAAATGGGAGTTCGTATGATTTCCCCA	300
*****		
LIC	ACAGGCGAAATCGGTGAACACAGGCGACGGAGACTTAGTAAGCGACGCTTTCAAAGCGGCT	359
LIG	ACAGGCGAAATCGGTGAACACAGGCGACGGAGACTTAGTAAGCGACGCTTTCAAAGCGGCT	360
LII	ACAGGCGAAATCGGTGAACACAGGCGACGGAGACTTAGTAAGCGACGCTTTCAAAGCGGCT	311
LIP	ACAGGCGAAATCGGTGAACACAGGCGACGGAGACTTAGTAAGCGACGCTTTCAAAGCGGCT	360
*****		
LIC	ACCCAGAGAAAAATCAATGCCACATTGGTTTGATACTTGGATCCGTGTAGAAAGAATG	419
LIG	ACCCAGAGAAAAATCAATGCCACATTGGTTTGATACTTGGATCCGTGTAGAAAGAATG	420
LII	ACCCAGAGAAAAATCAATGCCACATTGGTTTGATACTTGGATCCGTGTAGAAAGAATG	371
LIP	ACCCAGAGAAAAATCAATGCCACATTGGTTTGATACTTGGATCCGTGTAGAAAGAATG	420
*****		
LIC	TCGGCGATTATGCCTGACCAAATCGCCAAAGCTGCGAAAGCAAAACCCAGTTCAAAAATTG	479
LIG	TCGGCGATTATGCCTGACCAAATCGCCAAAGCTGCGAAAGCAAAACCCAGTTCAAAAATTG	480
LII	TCGGCGATTATGCCTGACCAAATCGCCAAAGCTGCGAAAGCAAAACCCAGTTCAAAAATTG	431
LIP	TCGGCGATTATGCCTGACCAAATCGCCAAAGCTGCGAAAGCAAAACCCAGTTCAAAAATTG	480
*****		
LIC	GACGATGATGATAATGGTGACGATACTTATAAAGAAGAGAGACACAACAAGTACAACCTCT	539
LIG	GACGATGATGATGATGGTGACGATACTTATAAAGAAGAGAGACACAACAAGTACAACCTCT	540
LII	GACGATGATGATGATGGTGACGATACTTATAAAGAAGAGAGACACAACAAGTACAACCTCT	491
LIP	GACGATGATGATGATGGTGACGATACTTATAAAGAAGAGAGACACAACAAGTACAACCTCT	540
*****		
LIC	CTTACTAGAATCAAGATCCCTAATCCTCCAAAATCTTTTGACGATCTGAAAAACATCGAC	599
LIG	CTTACTAGAATCAAGATCCCTAATCCTCCAAAATCTTTTGACGATCTGAAAAACATCGAT	600
LII	CTTACTAGAATCAAGATCCCTAATCCTCCAAAATCTTTTGACGATCTGAAAAACATCGAC	551
LIP	CTTACTAGAATCAAGATCCCTAATCCTCCAAAATCTTTTGACGATCTGAAAAACATCGAC	600
*****		
LIC	ACTAAAAAATCTTTTAGTAAGAGGTCTTTACAGAATTTCTTTCACTACCTACAAACCAGGT	659
LIG	ACTAAAAAATCTTTTAGTAAGAGGTCTTTACAGAATTTCTTTCACTACCTACAAACCAGGT	660
LII	ACTAAAAAATCTTTTAGTAAGAGGTCTTTACAGAATTTCTTTCACTACCTACAAACCAGGT	611
LIP	ACTAAAAAATCTTTTAGTAAGAGGTCTTTACAGAATTTCTTTCACTACCTACAAACCAGGT	660
*****		
LIC	GAAAGTGAAGGATCTTTTCGTTGCATCTGTTGGTCTGCTTTTCCACCAGGTATTCCAGGT	719
LIG	GAAAGTGAAGGATCTTTTCGTTGCATCTGTTGGTCTGCTTTTCCACCAGGTATTCCAGGT	720
LII	GAAAGTGAAGGATCTTTTCGTTGCATCTGTTGGTCTGCTTTTCCACCAGGTATTCCAGGT	671
LIP	GAAAGTGAAGGATCTTTTCGTTGCATCTGTTGGTCTGCTTTTCCACCAGGTATTCCAGGT	720
*****		
LIC	GTGAGCCCGCTGATCCACTCAAATCCTGAAGAATTGCAAAAACAAGCTATCGCTGCTGAA	779
LIG	GTGAGCCCGCTGATCCACTCAAATCCTGAAGAATTGCAAAAACAAGCTATCGCTGCTGAA	780
LII	GTGAGCCCGCTGATCCACTCAAATCCTGAAGAATTGCAAAAACAAGCTATCGCTGCTGAA	728
LIP	GTGAGCCCGCTGATCCACTCAAATCCTGAAGAATTGCAAAAACAAGCTATCGCTGCTGAA	780
*****		

>Candidate sequence for primer design (consensus)

GAAACCGTAAAAACGTTACTTCCCTACGGATCTGTGATCAACTATTACGGATACGTAAAGCCAGGACAAGCGCCGG  
ACGGTTTAGTCGATGGAACAAAAAAGCATATCTCTATGTTTGGATTCTGCGGTAATCGCTGAAATGGGAGT  
TCGTATGATTTCCCCAACAGGCGAAATCGGTGAACACAGGCGACGGAGACTTAGTAAGCGACGCTTTCAAAGCGGCT  
ACCCAGAGAAAAATCAATGCCACATTGGTTTGATACTTGGATCCGTGTAGAAAGAATGTCGGCGATTATGCCTG  
ACCAAATCGCCAAAGCTGCGAAAGCAAAACCCAGTTCAAAAATTGGACGATGATGATGATGGTGACGATACTTATAA  
AGAAGAGAGACACAACAAGTACAACCTCTTACTAGAATCAAGATCCCTAATCCTCCAAAATCTTTTGACGATCTG  
AAAAACATCGACACTAAAAAATCTTTTAGTAAGAGGTCTTTACAGAATTTCTTTCACTACCTACAAACCAGGTGAAG  
TGAAAGGATCTTTTCGTTGCATCTGTTGGTCTGCTTTTCCACCAGGTATTCCAGGTGTGAGCCCGCTGATCCACTC  
AAATCCTGAAGAATTGCAAAAACAAGCTATCGCTGCT

**Anexx 3:** *In silico* primer design (Invitrogen™Oliperfectdesign™)

Sequence Name:  
leptospira interrogans

Target Sequence:

```

1      10      20      30      40      50      60      70      80      90
1      CTATCTCTATGTTTGGATTCTGCGGTAATCGCTGAAATGGGAGTTCTGATGATTTCCCAACAGGCGAAATCGGTGAACAGGCGACGGAGACTTAGTA
101    AGCGACGCTTTCAAAGCGGCTACCCAGAGAAAAATCAATGCCACATTGGTTTGATACTTGGATCCGTGTAGAAAGAAATGTCGGCGATTATGCCTGACC
201    AAATCGCCAAAGCTGCGAAAGCAAAACAGTTCAAAAATTGGACGATGATGATAATGGTGACGATACTTATAAAGAGAGAGACACAACAAGTACAACTC
301    TCTTACTAGAATCAAGATCCCTAATCCTCCAAAATCTTTTGACGATCTGAAAAACATCGACACTAAAAAACTTTTAGTAAGAGGTCCTTACAGAAATTTCT
401    TTCCTACCTACAAACAGGTGAAGTGAAGGATCTTTCGTTGCATCTGTTGGTCTGCTTTTCCACCAGGTATTCAGGTGTGAGGCCGCTGATCCACT
501    CAAATCCTGAA
  
```

Rank: 1   Product Length: 480   Product Region: 9-488				
Primer Name	%GC	Strand	Size (bases)	Tm (°C)
<input type="checkbox"/> leptospira interrogans 1 F	45.00	FWD	20	60.33
<input type="checkbox"/> leptospira interrogans 1 R	55.00	REV	20	59.02
5' Addition		Primer Sequence		
<input type="checkbox"/>	<input type="checkbox"/>	A T G T T T G G A T T C C T G C C G T A		
<input type="checkbox"/>	<input type="checkbox"/>	G G C T C A C A C C T G G A A T A C C T		

**Anexx 4:** Custom digest with *BccI* (Bio Labs, NEBcutter).

